Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer - PubMed (original) (raw)

Review

. 2005 May-Jun;12(3):243-53.

Affiliations

• PMID: 15891269

Review

Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer

Leisha A Emens. Am J Ther. 2005 May-Jun.

Abstract

Breast cancers are a biologically heterogeneous group of mammary tumors with distinct natural histories and varied responses to established therapies. They have long been divided into those that are hormone sensitive [as defined by expression of the estrogen receptor alpha (ERalpha) and/or the progesterone receptor (PR)] and those that are not. Notably, only those breast cancers that express ERalpha and/or PR typically respond to hormonal therapy with tamoxifen, aromatase inhibitors, or the newer agent fulvestrant. More recently, the transmembrane tyrosine kinase receptor HER-2/neu was identified as an oncogene overexpressed by about 30% of breast cancers. These HER-2/neu-overexpressing breast cancers define a subset of breast tumors that are characteristically more aggressive, and women who develop them have a shorter survival. Trastuzumab (Herceptin), a humanized monoclonal antibody specific for HER-2/neu, has revolutionized the management of metastatic HER-2/neu-overexpressing breast cancers. As a single agent, it produces response rates similar to those of many single-agent chemotherapeutic agents active in metastatic breast cancer and has limited toxicity. Combining trastuzumab with chemotherapy can result in synergistic antitumor activity. The clear efficacy of trastuzumab against HER-2/neu-overexpressing metastatic breast cancer has led to a keen interest in testing its role in the management of early breast cancer, and multiple large clinical trials are currently in progress. This review summarizes the available clinical data on the use of trastuzumab in HER-neu-overexpressing breast cancer and briefly highlights emerging opportunities for innovative, trastuzumab-based breast cancer therapies.

PubMed Disclaimer

Similar articles

• Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer.
  Gonzalez-Angulo AM, Hortobágyi GN, Esteva FJ. Gonzalez-Angulo AM, et al. Oncologist. 2006 Sep;11(8):857-67. doi: 10.1634/theoncologist.11-8-857. Oncologist. 2006. PMID: 16951389 Review.
• Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells.
  Menendez JA, Vellon L, Lupu R. Menendez JA, et al. Med Hypotheses. 2005;64(5):997-1001. doi: 10.1016/j.mehy.2004.09.027. Med Hypotheses. 2005. PMID: 15780499
• HER-2/neu expression in primary and metastatic breast cancer.
  Lower EE, Glass E, Blau R, Harman S. Lower EE, et al. Breast Cancer Res Treat. 2009 Jan;113(2):301-6. doi: 10.1007/s10549-008-9931-6. Epub 2008 Feb 14. Breast Cancer Res Treat. 2009. PMID: 18273700
• Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
  Baselga J, Perez EA, Pienkowski T, Bell R. Baselga J, et al. Oncologist. 2006;11 Suppl 1:4-12. doi: 10.1634/theoncologist.11-90001-4. Oncologist. 2006. PMID: 16971734 Review.

Cited by

• IkappaB kinase alpha kinase activity is required for self-renewal of ErbB2/Her2-transformed mammary tumor-initiating cells.
  Cao Y, Luo JL, Karin M. Cao Y, et al. Proc Natl Acad Sci U S A. 2007 Oct 2;104(40):15852-7. doi: 10.1073/pnas.0706728104. Epub 2007 Sep 21. Proc Natl Acad Sci U S A. 2007. PMID: 17890319 Free PMC article.
• Oral vinorelbine: role in the management of metastatic breast cancer.
  Aapro MS, Conte P, Esteban González E, Trillet-Lenoir V. Aapro MS, et al. Drugs. 2007;67(5):657-67. doi: 10.2165/00003495-200767050-00002. Drugs. 2007. PMID: 17385939 Review.
• The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.
  de Leon J, Susce MT, Murray-Carmichael E. de Leon J, et al. Mol Diagn Ther. 2006;10(3):135-51. doi: 10.1007/BF03256453. Mol Diagn Ther. 2006. PMID: 16771600 Review.
• The changing role of pathology in breast cancer diagnosis and treatment.
  Leong AS, Zhuang Z. Leong AS, et al. Pathobiology. 2011;78(2):99-114. doi: 10.1159/000292644. Epub 2011 Jun 14. Pathobiology. 2011. PMID: 21677473 Free PMC article. Review.
• The role of the epidermal growth factor receptor in breast cancer.
  Chan SK, Hill ME, Gullick WJ. Chan SK, et al. J Mammary Gland Biol Neoplasia. 2006 Jan;11(1):3-11. doi: 10.1007/s10911-006-9008-2. J Mammary Gland Biol Neoplasia. 2006. PMID: 16947082 Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal